Lung Cancer
Conference Coverage
‘Unprecedented’ long-term survival after immunotherapy in pretreated NSCLC
Conference Coverage
Model could reduce some disparities in lung cancer screening
Conference Coverage
Customized chemotherapy did not improve survival in early NSCLC
Toxicity was less common with customized therapy.
Conference Coverage
Neoadjuvant atezolizumab safe for patients with resectable lung cancer
Neoadjuvant atezolizumab was deemed “effective, well tolerated, and surgically acceptable.”
Conference Coverage
Managing cancer outpatients during the pandemic: Tips from MSKCC
MSKCC has established guiding principles on how to manage cancer patients during the pandemic.
Conference Coverage
Death rates ‘remain high’ in patients with thoracic cancers and COVID-19
The risk of death was similar across racial and ethnic groups.
Conference Coverage
Nivolumab improves survival in relapsed mesothelioma
Nivolumab prolonged progression-free and overall survival, compared with placebo.
Conference Coverage
Screening for lung cancer in never-smokers is ‘feasible’
Never-smokers should be screened for lung cancer too, researchers say.
Conference Coverage
‘Astonishing’ 4-year survival in NSCLC with pembro plus chemo
New data showing a doubling in survival with the combination versus chemo alone have been hailed as “very impressive” by clinicians.
Conference Coverage
Pandemic seems to impact lung cancer diagnosis and prognosis
There was a 38% decrease in new lung cancer diagnoses during the pandemic, and 30-day mortality rates nearly doubled.